M&A Deal Summary

MilliporeSigma Acquires HUB

On December 17, 2024, MilliporeSigma acquired life science company HUB

Acquisition Highlights
  • This is MilliporeSigma’s 2nd transaction in the Life Science sector.
  • This is MilliporeSigma’s 1st transaction in the Netherlands.

M&A Deal Summary

Date 2024-12-17
Target HUB
Sector Life Science
Buyer(s) MilliporeSigma
Deal Type Add-on Acquisition

Target

HUB

Utrecht, Netherlands
HUB offers patient-derived organoid technology that enables drug developers to identify and validate clinical candidates in a patient-relevant in vitro system. HUB Organoid Technology represents a paradigm shift for drug discovery and development, preclinical patient stratification, predictive diagnostics, personalized medicine, clinical trials, regenerative medicine, and companion diagnostics. HUB offers licenses to its proprietary technology and provides drug development services using its living organoid biobanks. HUB is based in Utrecht, Netherlands.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

MilliporeSigma

Burlington, Massachusetts, United States

Category Company
Sector Life Science
DESCRIPTION

MilliporeSigma is a provider of U.S. and Canada life science business of of Merck KGaA.


DEAL STATS #
Overall 3 of 3
Sector: Life Science M&A 2 of 2
Type: Add-on Acquisition M&A Deals 1 of 1
Country: Netherlands M&A 1 of 1
Year: 2024 M&A 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-05-22 Mirus Bio

Madison, Wisconsin, United States

Mirus Bio is a developer of biomimetic, cell-adaptive lipid-polymer nanocomplexes (LPNCs) for nucleic acid delivery. Mirus Bio's expertise in nucleic acid delivery gives life scientists the most advanced tools for gene expression, biotherapeutic protein production, virus manufacturing, and genome editing. Mirus Bio was founded in 1995 and is based in Madison, Wisconsin.

Buy $600M